Tag: MNMD Stock


MindMed (NASQAD: MNMD) Begins Clinical Trials For DMT

MindMed (NASQAD: MNMD) recently announced the start of Phase 1 clinical trials, assessing the safety, pharmacokinetics, and pharmacodynamics of DMT. The drug is a naturally occurring psychedelic and an active ingredient in ayahuasca. MindMed is a leading biotech company reputed for making psychedelic-inspired therapies. Collaborating with Liechti LAb The results […]